放射性核素标记RGD多肽在整合素受体显像中的应用

陈素芸

陈素芸

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 3: (129-132)

引用本文:

Citation:

放射性核素标记RGD多肽在整合素受体显像中的应用

陈素芸

200025 上海, 上海交通大学瑞金医院核医学科
中图分类号: R817.4

Application of radiolabeled RGD peptides in imaging of integrin receptor

CHEN Su-yun

Department of Nuclear Medicine, Shanghai Ruijin Hospital Affiliated Shanghai Jiaotong University, Shanghai 200025, China
CLC number: R817.4

摘要: 整合素受体α_vβ₃在新生血管及多种恶性肿瘤细胞表面有高水平的表达,在肿瘤的生长、局部浸润和转移中,特别是肿瘤诱导的血管生成中发挥重要作用。由于放射性核素标记的精氨酸-甘氨酸-天冬氨酸(RGD)多肽能够与受体特异性地识别结合,因此目前被逐渐应用于肿瘤整合素表达水平的受体显像中。
- 受体,玻连蛋白 /
- 肽类 /
- 放射性核素显像 /
- 精氨酸-甘氨酸-天冬氨酸
Abstract: Integrin α_vβ₃ is highly expressed on activated endothelial cells during angiogenesis and sollid tumor cells. It has been shown to play an essential role in the regulation of tumor growth, local invasiveness, metastatic potential, especially in angiogenesis. Radiolabeld peptides including the tripeptide sequence arginine-glycine-aspartic acid (single-letter code RGD), which can bind to the α_vβ₃ integrin with high affinity and selectivity, have been developed for determination of α_vβ₃ integrin expression.
- Receptor,vitronectin /
- Peptides /
- Radionuclide imaging /
- Arginine-glycine-aspartic acid
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Danen EH.Integrins:regulators of tissue function and cancer progression.Curr Pharm Des,2005,11(7):881-891.
[2]	Folkman J,Addressing tumor blood vessels.Nature Biotechnol,1997,15(6):510.
[3]	Kumar CC.Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis.Curr Drug Targets,2003,4(2):123-131.
[4]	Teti A,Migliaccio S,Baron R.The role of alphavbeta3 integrin in the development of osteolytic bone metastases:a pharmacological target for alternative therapy?.Calcif Tissue Int,2002,71(4):293-299.
[5]	Raguse JD,Gath HJ,Bier J,et al.Gilengitide (EMD121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.Oral Oncol,2004,40(2):228-230.
[6]	Plersehbacher MD,Ruoslahti E.The cell attachment activity of flibronectin call be duplicated by small fragments of the molecule.Nature,1984,309:30-33
[7]	Van Hagen PM,Breeman WA,Bernard HF,et al.Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy.Int J Cancer,2000,90(4):186-198.
[8]	Haubner R,Wester HJ,Burkhart F,et al.Glycosylated RGD-containing peptides:tracer for tumor targeting and angiogenesis imaging with improved biokinetics.J Nucl Med,2001,42(2):326-336.
[9]	Haubner R,Wester HJ,Weber WA,et al.Noninvasive imaging of alpha(v) beta3 integrin expression using ¹⁸F-labeled RGD-containing giycopeptide and positron emission tomography.Cancer Res,2001,61(5):1781-1785.
[10]	Haubner R,Weber WA,Beer AJ,et al.Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.PLoS Med,2005,2(3):e70.
[11]	Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the αvβ3-selective tracer ¹⁸F-galacto-RGD in cancer patients.J Nucl Med,2005,46(8):1333-1341.
[12]	Chen X,Park R,Hou Y,et al,MicroPET imaging of brain tumor angiogenesis with ¹⁸F-labeled PEGylated RGD peptide.Eur J Nucl Med Moi Imaging,2004,31(8):1081-1089.
[13]	Chen X,Park R,Tohme M,et al.MicroPET and autoradiographic imaging of breast cancer α v-integrin expression using ¹⁸F-and ⁶⁴Cu-labeled RGD peptide.Bioconjug Chem,2004,15(1):41-49.
[14]	Chen X,Hou Y,Tohme M,et al.Pegylated Arg-Gly-Asp peptide:⁶⁴Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.J Nucl Med,2004,45(10):1776-1783.
[15]	Chen X,Liu S,Hou Y,et al.MicroPET imaging of breast cancer alpha v-integrin expression with ⁶⁴Cu-labeled dimeric RGD peptides.Mol Imaging Biol,2004,6(5):350-359.
[16]	Chen X,Sievers E,Hou Y,et al.Integrin αvβ3-targeted imaging of lungcancer.Neoplasia,2005,7(3):271-279.
[17]	Dayton PA,Pearson D,Clark J,et al.Ultrasonic analysis of peptide-and antibody-targeted microbubble contrast agents for molecular imaging of αvβ3-expressing cells.Mol Imaging,2004,3(2):125-134.
[18]	Anderson SA,Rader RK,Westiin WF,et al.Magnetic resonance contrast enhancement of neovasculature with αvβ3-targeted nanoparli-cles.Magn Reson Med,2000,44(3):433-439.
[19]	Haubner R,Wester HJ.Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.Curr PharmDes,2004,10(13):1439-1455.

[1]	刘晓飞 , 张锦明 , 王洁磊 , 田嘉禾 . 放射性核素标记RGD序列多肽与整合素α_vβ₃受体显像的研究进展. 国际放射医学核医学杂志, 2008, 32(1): 12-15.
[2]	肖晴 , 潘芯 , 李崇佼 , 蒋亚群 , 王怡春 , 文兵 , 雷萍 , 何勇 . 转铁蛋白受体靶向分子探针⁹⁹Tc^m-T7的放射性标记及肿瘤显像研究. 国际放射医学核医学杂志, 2022, 46(4): 223-229. doi: 10.3760/cma.j.cn121381-202110017-00167
[3]	王浩 , 施培基 , 周晓靓 , 王荣先 . RGD肽及其衍生物在肿瘤显像及治疗中的研究进展. 国际放射医学核医学杂志, 2007, 31(5): 274-277.
[4]	潘越 , 王观筠 , 党浩丹 , 徐白萱 . RGD肽类示踪剂及其PET显像在脑胶质瘤诊疗中的应用. 国际放射医学核医学杂志, 2023, 47(6): 362-366. doi: 10.3760/cma.j.cn121381-202207012-00299
[5]	邵国强 , 王自正 . 整合素αvβ3受体靶向肿瘤显像研究进展. 国际放射医学核医学杂志, 2014, 38(1): 33-36. doi: 10.3760/cma.j.issn.1673-4114.2014.01.007
[6]	褚丽萍 , 王彦 , 王月英 , 刘金剑 , 吴红英 , 刘鉴峰 . 多肽类肺癌显像剂的制备及其初步鉴定. 国际放射医学核医学杂志, 2010, 34(3): 135-138. doi: 10.3760/cma.j.issn.1673-4114.2010.03.002
[7]	颜成龙 , 周杏琴 , 曹国宪 . N-甲基-D-天冬氨酸受体显像剂研究进展. 国际放射医学核医学杂志, 2009, 33(1): 9-13. doi: 10.3760/cma.j.issn.1673-4114.2009.01.009
[8]	孔艳艳 , 周杏琴 , 曹国宪 . N-甲基-D-天冬氨酸受体与脑卒中的关系及其核素显像剂. 国际放射医学核医学杂志, 2010, 34(1): 6-11. doi: 10.3760/cma.j.issn.1673-4114.2010.01.002
[9]	夏俊勇 , 王火强 . 以血管内皮生长因子及其受体为靶向的肺癌放射性核素显像. 国际放射医学核医学杂志, 2008, 32(2): 82-85.
[10]	王培 , 王帅亮 , 朱华 , 杨志 . 放射性核素探针在嵌合抗原受体T细胞治疗显像中的应用. 国际放射医学核医学杂志, 2023, 47(5): 302-307. doi: 10.3760/cma.j.cn121381-202206010-00290